Converting fibroblast cells into induced pluripotent stem cells
Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells
Hadassah Medical Organization · NCT00801372
This study is testing whether skin cells can be turned into special stem cells that might help with future medical treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hadassah Medical Organization (other) |
| Locations | 1 site (Jerusalem, Israel) |
| Trial ID | NCT00801372 on ClinicalTrials.gov |
What this trial studies
This project aims to develop human induced pluripotent stem (iPS) cells from existing fibroblast lines originally donated for clinical applications. The study will explore the reprogramming process of somatic cells into an embryonic state and investigate the properties and potential of these iPS cells. Various experimental systems will be employed to characterize the iPS cells, focusing on their biology, developmental potential, and ability to differentiate into functional cell types. The research will be conducted under Good Manufacturing Practice (GMP) conditions to ensure suitability for future clinical applications.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy individuals aged 18 and older.
Not a fit: Patients who are not healthy or younger than 18 years old will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could provide a limitless source of cells for transplantation and regenerative medicine.
How similar studies have performed: Other studies have shown promise in the field of induced pluripotent stem cells, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * healthy, older than 18 Exclusion Criteria: * non healthy, younger than 18
Where this trial is running
Jerusalem, Israel
- Hadassah Ein Kerem — Jerusalem, Israel, Israel (RECRUITING)
Study contacts
- Principal investigator: Benjamin E Reubinoff, MD PhD — Chairman of Department of Obstetrics & Gynecology/IVF, Hadassah Ein Kerem
- Study coordinator: Benjamin E Reubinoff, MD PhD
- Email: benjaminr@ekmd.huji.ac.il
- Phone: 011-972-2-6774569
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pregnant, Healthy Females, Healthy Male Newborns, termination of pregnancy, surgical circumcision, umbilical cord